[Expression and clinical significance of @entity1262 gene in XXXX ].

@entity1 @entity1262 @entity71083 @entity706 @entity7895
BACKGROUND _ OBJECTIVE: It is still unclear whether overexpression of @entity1262 gene play a role in the chemotherapy resistance of @entity706 . This study was designed to investigate P-glycoprotein( @entity7895 ) and @entity1262 mRNA levels of @entity706 and to observed the impact of @entity7895 level upon chemotherapy response. METHODS: Ten samples of relapsed @entity706 and 21 samples of untreated @entity706 were assessed by flow cytometry(FCM). The @entity1262 mRNA levels were determined by real-time reverse-transcription PCR assay simultaneously in eighteen samples. The impact of @entity7895 levels upon chemotherapy response was observed in seventeen @entity1 . RESULTS: Nineteen Percent (4/21) @entity1 overexpressed @entity7895 at diagnosis as compared to 60%(6/10) in relapse(P = 0.012). The copy numbers of @entity1262 mRNA were 4 x 10(2)-1.32 x 10(4) copies/microgram RNA in untreated group and 4 x 10(2)-4 x 10(4) copies/microgram RNA in recurrent group. There existed significant difference in the distribution of @entity1262 mRNA expression between these two groups, P < 0.05. The complete response rates were 46% (6/13) in @entity7895 non-overexpression group and 25% (1/4) in @entity7895 overexpression group(P = 0.60). CONCLUSION: @entity706 highly express @entity71083 mRNA. The overexpression of @entity1262 gene may play a role in the multidrug resistance of relapsed @entity706 .
